Examining Concerns Regarding FDA's Proposed Changes to Generic Drug Labeling.

Generic drug utilization in the Medicare Part D program.
Published: (2007)

Authorized generic drugs : short-term effects and long-term impact.
Published: (2011)

FDA Risk Evaluation and Mitigation Strategies (REMS) : description and effect on generic drug development /
by: Dabrowska, Agata
Published: (2018)

Examining FDA's Prescription Drug User Fee Program.
Published: (2017)

FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session.
Published: (1989)

Making Objective Drug Evidence Revisions for New Labeling Act of 2020 : report (to accompany H.R. 5668) (including cost estimate of the Congressional Budget Office).
Published: (2020)

FDA-approved bargain drugs : generic products must meet high standards.
Published: (2003)

Generic drugs : stakeholders views on improving FDA's information on patents : report to congressional committees /
Published: (2023)

The impact of high-priced generic drugs on Medicare and Medicaid.
Published: (1998)

The marketing of generic drugs : a guide to counter-strategies for the technology intensive pharmaceutical companies /
by: James, Barrie G.
Published: (1981)

Generic Drug User Fee Amendments : Accelerating Patient Access to Generic Drugs.
Published: (2016)

FDA has made progress on oversight and inspections of manufacturers of generic drugs.
Published: (2015)

Prescription drugs : implications of drug labeling and off-label use : statement of Sarah F. Jagger, Director of Health Services Quality and Public Health Issues, Health, Education, and Human Services Division, before the Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Reform and Oversight, U.S. House of Representatives /
by: Jagger, Sarah F.
Published: (1996)

FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session.
Published: (1989)

Generic drug laws : a decade of trial, a prescription for progress /
Published: (1986)

Entry threats and pricing in the generic drug industry /
by: Wendling, Brett
Published: (2010)

Antitrust Concerns and the FDA Approval Process.
Published: (2017)

FDA's generic drug application policy : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, second session, July 28, 1988.
Published: (1989)

FDA's generic drug enforcement and approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, March 7 and June 5, 1991.
Published: (1992)

Biosimilar Implementation : A Progress Report from FDA.
Published: (2015)

Expanding the use of generic drugs.
Published: (2010)

FDA warning letters : trends and perspectives.
Published: (1999)

FDA warning letters : timeliness and effectiveness.
Published: (1999)

Examining the Impact of Voluntary Restricted Distribution Systems in the Pharmaceutical Supply Chain.
Published: (2017)

Developments in the Prescription Drug Market : Oversight.
Published: (2016)

The effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-day exclusivity period /
by: Olson, Luke M., et al.
Published: (2013)

Increasing generic drug use : savings for seniors and Medicare : hearing before the Special Committee on Aging, United States Senate, One Hundred Ninth Congress, second session, Washington, DC, September 21, 2006.
Published: (2007)

Increasing generic drug use : savings for seniors and Medicare : hearing before the Special Committee on Aging, United States Senate, One Hundred Ninth Congress, second session, Washington, DC, September 21, 2006.
Published: (2007)

Generic drugs : saving money at the pharmacy.
Published: (1998)

Risk evaluation and mitigation strategies (REMS) and generic drugs /
by: Dabrowska, Agata
Published: (2018)

Facts about generic drugs.
Published: (2006)

Generic drug product development : solid oral dosage forms /
Published: (2005)

Journal of generic medicines.
Published: (2003)

Prioritizing Public Health : The FDA's Role in the Generic Drug Marketplace : Special Hearing.
Published: (2016)

Perspectives of drug manufacturers : abbreviated new drug applications.
Published: (1990)

The generic drug maze : speeding access to affordable life-saving drugs : hearing before the Special Committee on Aging, United States Senate, One Hundred Ninth Congress, second session, Washington, DC, July 20, 2006.
Published: (2006)